A novel single-chain antibody redirects adenovirus to IL13Rα2-expressing brain tumors

Julius W. Kim, Jacob S. Young, Elena Solomaha, Deepak Kanojia, Maciej S Lesniak, Irina V Balyasnikova*

*Corresponding author for this work

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The generation of a targeting agent that strictly binds to IL13Rα2 will significantly expand the therapeutic potential for the treatment of IL13Rα2-expressing cancers. In order to fulfill this goal, we generated a single-chain antibody (scFv47) from our parental IL13Rα2 monoclonal antibody and tested its binding properties. Furthermore, to demonstrate the potential therapeutic applicability of scFv47, we engineered an adenovirus by incorporating scFv47 as the targeting moiety in the viral fiber and characterized its properties in vitro and in vivo. The scFv47 binds to human recombinant IL13Rα2, but not to IL13Rα1 with a high affinity of 0.9 · 10-9 M, similar to that of the parental antibody. Moreover, the scFv47 successfully redirects adenovirus to IL13Rα2 expressing glioma cells both in vitro and in vivo. Our data validate scFv47 as a highly selective IL13Rα2 targeting agent and justify further development of scFv47-modified oncolytic adenovirus and other therapeutics for the treatment of IL13Rα2-expressing glioma and other malignancies.

Original languageEnglish (US)
Article number18133
JournalScientific reports
Volume5
DOIs
StatePublished - Dec 14 2015

Fingerprint

Single-Chain Antibodies
Adenoviridae
Brain Neoplasms
Glioma
Neoplasms
Therapeutics
Monoclonal Antibodies
Antibodies
In Vitro Techniques

ASJC Scopus subject areas

  • General

Cite this

@article{7efda26159d14c17924b49f5604d20dd,
title = "A novel single-chain antibody redirects adenovirus to IL13Rα2-expressing brain tumors",
abstract = "The generation of a targeting agent that strictly binds to IL13Rα2 will significantly expand the therapeutic potential for the treatment of IL13Rα2-expressing cancers. In order to fulfill this goal, we generated a single-chain antibody (scFv47) from our parental IL13Rα2 monoclonal antibody and tested its binding properties. Furthermore, to demonstrate the potential therapeutic applicability of scFv47, we engineered an adenovirus by incorporating scFv47 as the targeting moiety in the viral fiber and characterized its properties in vitro and in vivo. The scFv47 binds to human recombinant IL13Rα2, but not to IL13Rα1 with a high affinity of 0.9 · 10-9 M, similar to that of the parental antibody. Moreover, the scFv47 successfully redirects adenovirus to IL13Rα2 expressing glioma cells both in vitro and in vivo. Our data validate scFv47 as a highly selective IL13Rα2 targeting agent and justify further development of scFv47-modified oncolytic adenovirus and other therapeutics for the treatment of IL13Rα2-expressing glioma and other malignancies.",
author = "Kim, {Julius W.} and Young, {Jacob S.} and Elena Solomaha and Deepak Kanojia and Lesniak, {Maciej S} and Balyasnikova, {Irina V}",
year = "2015",
month = "12",
day = "14",
doi = "10.1038/srep18133",
language = "English (US)",
volume = "5",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

A novel single-chain antibody redirects adenovirus to IL13Rα2-expressing brain tumors. / Kim, Julius W.; Young, Jacob S.; Solomaha, Elena; Kanojia, Deepak; Lesniak, Maciej S; Balyasnikova, Irina V.

In: Scientific reports, Vol. 5, 18133, 14.12.2015.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A novel single-chain antibody redirects adenovirus to IL13Rα2-expressing brain tumors

AU - Kim, Julius W.

AU - Young, Jacob S.

AU - Solomaha, Elena

AU - Kanojia, Deepak

AU - Lesniak, Maciej S

AU - Balyasnikova, Irina V

PY - 2015/12/14

Y1 - 2015/12/14

N2 - The generation of a targeting agent that strictly binds to IL13Rα2 will significantly expand the therapeutic potential for the treatment of IL13Rα2-expressing cancers. In order to fulfill this goal, we generated a single-chain antibody (scFv47) from our parental IL13Rα2 monoclonal antibody and tested its binding properties. Furthermore, to demonstrate the potential therapeutic applicability of scFv47, we engineered an adenovirus by incorporating scFv47 as the targeting moiety in the viral fiber and characterized its properties in vitro and in vivo. The scFv47 binds to human recombinant IL13Rα2, but not to IL13Rα1 with a high affinity of 0.9 · 10-9 M, similar to that of the parental antibody. Moreover, the scFv47 successfully redirects adenovirus to IL13Rα2 expressing glioma cells both in vitro and in vivo. Our data validate scFv47 as a highly selective IL13Rα2 targeting agent and justify further development of scFv47-modified oncolytic adenovirus and other therapeutics for the treatment of IL13Rα2-expressing glioma and other malignancies.

AB - The generation of a targeting agent that strictly binds to IL13Rα2 will significantly expand the therapeutic potential for the treatment of IL13Rα2-expressing cancers. In order to fulfill this goal, we generated a single-chain antibody (scFv47) from our parental IL13Rα2 monoclonal antibody and tested its binding properties. Furthermore, to demonstrate the potential therapeutic applicability of scFv47, we engineered an adenovirus by incorporating scFv47 as the targeting moiety in the viral fiber and characterized its properties in vitro and in vivo. The scFv47 binds to human recombinant IL13Rα2, but not to IL13Rα1 with a high affinity of 0.9 · 10-9 M, similar to that of the parental antibody. Moreover, the scFv47 successfully redirects adenovirus to IL13Rα2 expressing glioma cells both in vitro and in vivo. Our data validate scFv47 as a highly selective IL13Rα2 targeting agent and justify further development of scFv47-modified oncolytic adenovirus and other therapeutics for the treatment of IL13Rα2-expressing glioma and other malignancies.

UR - http://www.scopus.com/inward/record.url?scp=84949908750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949908750&partnerID=8YFLogxK

U2 - 10.1038/srep18133

DO - 10.1038/srep18133

M3 - Article

VL - 5

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 18133

ER -